Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempega | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  24680 of 24955  at  5/22/2020 9:16:12 PM  by

mathlover


 In response to msg 24678 by  Pacific
view thread

Re: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal

 "How are you determining that? 1L RCC ORR was 71.4% (10/14; 7.1% CR, 64.3% PR) and ORR of 28.6% (2/7, all PRs) in 2L I-O naive pts. It’s early data, with small n."
 
Healthy patients, only 1 out of 22 are poor risk, 9 out of 22 favorable risk.
 
IO naive second line ORR not great.  DCR 1st line 76%, second line 86%.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 255
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...